
Helen L Lowe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1739452/publications.pdf Version: 2024-02-01



HELENLLOWE

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Phase 0 study of vandetanib-eluting radiopaque embolics as a pre-operative embolization treatment in patients with resectable liver malignancies. Journal of Vascular and Interventional Radiology, 2022, , . | 0.5 | 0 |
| 2 | Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2021, 39, 3352-3363. | 1.6 | 59 |
| 3 | AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL. Blood, 2019, 134, 226-226. | 1.4 | 6 |
| 4 | EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer Journal of Clinical Oncology, 2019, 37, TPS6091-TPS6091. | 1.6 | 4 |
| 5 | VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. JMIR Research Protocols, 2019, 8, e13696. | 1.0 | 4 |
| 6 | Abstract CT105: AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL. , 2019, , . | | 0 |
| 7 | Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion. Blood, 2019, 134, 776-776. | 1.4 | 3 |
| 8 | Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451. | 27.8 | 1,287 |
| 9 | Tracking the Evolution of Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2109-2121. | 27.0 | 1,786 |
| 10 | Feasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a biomarker in advanced endometrial cancer (aEC) Journal of Clinical Oncology, 2014, 32, 5600-5600. | 1.6 | 0 |
| 11 | Antibody Directed Enzyme Prodrug Therapy (ADEPT). , 2009, , 336-349. | | 0 |